Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on AIM ImmunoTech but lowered the price target from $5.25 to $5.
September 03, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendiant Capital has maintained its Buy rating on AIM ImmunoTech but reduced the price target from $5.25 to $5, indicating a slight decrease in expected valuation.
The maintenance of a Buy rating suggests continued confidence in AIM ImmunoTech's prospects, but the lowered price target indicates a tempered outlook on its valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100